Jun 6 |
Biodexa Pharmaceuticals files to sell 2.49B ordinary shares for holders
|
Jun 3 |
Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer
|
May 22 |
Biodexa Pharmaceuticals receives $7M of gross proceeds
|
May 22 |
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
|
May 21 |
Biodexa rallies 80% on positive Phase 2 data for eRapa
|
May 21 |
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
|
May 15 |
Posting of Annual Report & Notice of AGM - Total Voting Rights
|
May 9 |
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
|
Apr 30 |
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
|
Apr 29 |
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
|